Property | Value |
?:abstract
|
-
COVID-19, the human coronavirus disease caused by SARS-CoV-2, was reported for the first time in Wuhan, China in late 2019. COVID-19 has no preventive vaccine or proven standard pharmacological treatment, and consequently, the outbreak swiftly became a pandemic affecting more than 215 countries around the world. For the diagnosis of COVID-19, the only reliable diagnostics is a qPCR assay. Among other diagnostic tools, the CRISPR-Cas system is being investigated for rapid and specific diagnosis of COVID-19. The CRISPR-Cas-based methods diagnose the SARS-CoV-2 infections within an hour. Apart from its diagnostic ability, CRISPR-Cas system is also being assessed for antiviral therapy development; however, till date, no CRISPR-based therapy has been approved for human use. The Prophylactic Antiviral CRISPR in huMAN cells (PAC-MAN), which is Cas 13 based strategy, has been developed against coronavirus. Although this strategy has the potential to be developed as a therapeutic modality, it may face significant challenges for approval in human clinical trials. This review is focused on describing potential use and challenges of CRISPR-Cas based approaches for the development of rapid and accurate diagnostic technique and/or a possible therapeutic alternative for combating COVID-19. The assessment of potential risks associated with use of CRISPR will be important for future clinical advancements.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
|
?:doi
|
-
10.3389/fcimb.2020.576875
|
?:journal
|
-
Front_Cell_Infect_Microbiol
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/d2d9eda54d95a515d872bdb88baf6d418ddfa8db.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7673385.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics
|
?:type
|
|
?:year
|
|